Key result
ARBs improve erectile function, while diuretics, non-selective MRAs, and most beta-blockers worsen it.
Why the study?
Erectile dysfunction is common among men over 40 years old, and both cardiovascular diseases and the medications used to treat them can affect erectile function.
Do cardiovascular drugs affect erectile function in males with cardiovascular diseases?
Do cardiovascular drugs affect erectile function in males with cardiovascular diseases?
Cardiovascular drug classes vary in their effects on erectile function—with ARBs showing positive effects and most beta-blockers, diuretics, and non-selective MRAs linked to erectile dysfunction—highlighting the need for individualized therapy to maintain treatment adherence.
Answers are grounded in this paper and cite their sources.
ARBs may preserve erectile function in men with hypertension; leaves open optimal drug selection pending randomized trials.
Erectile dysfunction (ED) is a common problem among the male population over 40 years old. Arterial hypertension, dyslipidemia and other cardiovascular diseases (CVDs), as well as some of the medications which are used to treat CVDs can affect erectile function (EF). This article discusses current data about cardiovascular drugs effect on EF and analyzes scientific literature from the following scientific databases: PubMed, ScienceDirect, and eLIBRARY.RU. Angiotensin II receptor blockers have a positive effect on EF. ED, as one of the possible side effects, can be observed during treatment by most beta-blockers (with the exception of nebivolol), diuretics, and non-selective mineralocorticoid receptor antagonists. There is no convincing evidence of a negative effect of angiotensin-converting enzyme inhibitors, calcium channel blockers, selective mineralocorticoid receptor antagonists, and metoprolol on EF. The data of the effect of statin therapy on EF is contradictory. There is a limited number of studies about interaction between angiotensin receptors, neprilysin inhibitors and EF. In many studies subjective methods of EF assessment are used. CVDs and ED have common risk factors and pathogenic mechanisms. Large-scale biobank studies using Mendelian randomization show that ED is more strongly associated with the presence of CVDs rather than with the medications. To clarify CVD drugs effects on EF it is necessary to conduct studies with objective assessment of EF using nighttime penile tumescence monitoring. Knowledge of the characteristics of CVD drugs allows doctors to provide patient with an individualized therapy without adverse events, and ensures a high level of patient adherence to treatment.
No takes yet. Share an insight, caveat, or question.
Raevskii et al. (2026) conducted a review in Erectile dysfunction and cardiovascular diseases. Cardiovascular drugs (ARBs, beta-blockers, diuretics, MRAs, ACEIs, CCBs, statins, ARNIs) was evaluated on Erectile function (EF) / Erectile dysfunction (ED). Angiotensin II receptor blockers positively affect erectile function, whereas most beta-blockers (except nebivolol), diuretics, and non-selective MRAs are associated with erectile dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: